p-Phenylenediamine
RTECS #
SS8050000
CAS #
Updated
March 2019
Molecular Weight
108.16
Molecular Formula
C6H8N2
Synonyms
1,4-Benzenediamine (9CI)
1,4-Diaminobenzene
1,4-Phenylenediamine
4-Aminoaniline
6PPD
BASF ursol D
Benzofur D
C.I. 76060
C.I. Developer 13
C.I. Oxidation Base 10
Developer 13
Developer PF
Durafur Black R
Fenylenodwuamina (Polish)
Fouramine D
Fourrine 1
Fourrine D
Fur Black 41867
FUR Brown 41866
Fur Yellow
Furro D
Futramine D
Nako H
Orsin
Oxidation Base 10
p-Aminoaniline
Paraphenylen-diamine
p-Benzenediamine
p-Diaminobenzene
Pelagol D
Pelagol DR
Pelagol Grey D
Peltol D
p-Fenylendiamin (Czech)
p-Phenylenediamine (ACGIH:OSHA)
Renal PF
Rodol D
Santoflex IC
Tertral D
Ursol D
USAF EK-394
Zoba Black D
1,4-Diaminobenzene
1,4-Phenylenediamine
4-Aminoaniline
6PPD
BASF ursol D
Benzofur D
C.I. 76060
C.I. Developer 13
C.I. Oxidation Base 10
Developer 13
Developer PF
Durafur Black R
Fenylenodwuamina (Polish)
Fouramine D
Fourrine 1
Fourrine D
Fur Black 41867
FUR Brown 41866
Fur Yellow
Furro D
Futramine D
Nako H
Orsin
Oxidation Base 10
p-Aminoaniline
Paraphenylen-diamine
p-Benzenediamine
p-Diaminobenzene
Pelagol D
Pelagol DR
Pelagol Grey D
Peltol D
p-Fenylendiamin (Czech)
p-Phenylenediamine (ACGIH:OSHA)
Renal PF
Rodol D
Santoflex IC
Tertral D
Ursol D
USAF EK-394
Zoba Black D
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| skin /Dog | 250 mg/24H | mild | JSCCA5 23,371,1972 |
| skin /guinea pig | 250 mg/24H | mild | JSCCA5 23,371,1972 |
| skin /human | 250 mg/24H | mild | JSCCA5 23,371,1972 |
| skin /man | 1% | CODEDG 61,236,2009 | |
| skin /man | 1% | moderate | CODEDG 56,366,2007 |
| skin /mouse | 250 mg/24H | mild | JSCCA5 23,371,1972 |
| skin /pig | 250 mg/24H | mild | JSCCA5 23,371,1972 |
| skin /rabbit | 12500 µg/24H | mild | FCTXAV 15,607,1977 |
| skin /rabbit | 250 mg/24H | moderate | JSCCA5 23,371,1972 |
| skin /woman | 1% | CODEDG 60,118,2009 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | ovary/hamster | 15 mg/L | EMMUEG 27,67,1996 |
| DNA adduct | other cell types/human | 100 mg/L | TOLED5 239,194,2015 |
| DNA Damage | fibroblast/hamster | 100 mg/L/3H | MUTAEX 29,37,2014 |
| DNA Damage | other cell types/human | 900 mg/L | MUTAEX 29,37,2014 |
| DNA Damage | fibroblast/hamster | 600 mg/L | MUTAEX 29,37,2014 |
| DNA Damage | other cell types/human | 100 mg/L/4H | TOLED5 239,194,2015 |
| DNA Damage | other cell types/human | 2 mg/L/24H | TOLED5 170,116,2007 |
| DNA inhibition | oral/mouse | 200 mg/kg | MUREAV 46,305,1977 |
| micronucleus test | lung/hamster | 156 µmol/L/6H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| micronucleus test | lung/hamster | 313 µmol/L/6H (+enzymatic activation step) | MUTAEX 26,709,2011 |
| micronucleus test | lung/hamster | 20 µmol/L/24H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| micronucleus test | lung/hamster | 78 µmol/L/48H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| morphological transform | embryo/rat | 1850 ng/plate | JJATDK 1,190,1981 |
| mutation in microorganisms | /Salmonella typhimurium | 33 µg/plate (+enzymatic activation step) | MUTAEX 29,37,2014 |
| mutation in microorganisms | /Salmonella typhimurium | 2 µmol/plate (+enzymatic activation step) | 45OHAA -,170,1980 |
| mutation in microorganisms | /Salmonella typhimurium | 1 µg/plate (-enzymatic activation step) | MUREAV 188,185,1987 |
| phage inhibition capacity | /Escherichia coli | 125 µg/well | MUREAV 260,349,1991 |
| sex chromosome loss and nondisjunction | oral/Drosophila melanogaster | 15500 µmol/L/3D | MUREAV 48,181,1977 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| subcutaneous/rat | lowest published toxic dose: 2625 mg/kg/30W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Tumorigenic: Tumors at site of application | KJMSAH 9,94,1958 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 25,2124,2011 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (5 percent kill): 6770 mg/L/30M | In Vitro Toxicity Studies: Cell counting | TIVIEQ 27,857,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 36.7 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 26,1150,2012 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 2.09 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,1150,2012 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 27 mg/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 30,318,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 27 mg/L/48H | Immunological Including Allergic: Increase in cellular immune response | TIVIEQ 30,318,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 27 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 30,318,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: >10 µmol/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,32,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 5438 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,32,2015 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 10 µmol/L | In Vitro Toxicity Studies: Other assays | TOLED5 239,32,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): 21 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 3 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 50 µmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXAPA9 256,35,2011 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 5000 mg/L/2H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1233,2013 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 218 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 199,51,2010 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 218 µmol/L/2H | In Vitro Toxicity Studies: Other assays | TOLED5 199,51,2010 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 27.5 µmol/L/24H | In Vitro Toxicity Studies: Phototoxicity in vitro | TIVIEQ 27,103,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 162.2 mg/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,314,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 162.2 mg/L/4H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,314,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 55 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 28,13,2014 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 5.0 µmol/L/48H | In Vitro Toxicity Studies: Other assays | TXAPA9 245,281,2010 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 27.2 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1127,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 46 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,1135,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 6.88 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1135,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 2 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXAPA9 283,147,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 0.4 µmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXAPA9 283,147,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 30 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,194,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 25 mg/L/48H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,194,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 100 mg/L/1H | In Vitro Toxicity Studies: Other assays | TOLED5 239,194,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 40 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,194,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 35 mg/L/48H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,194,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 351 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 349 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): 316.9 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): 279.8 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 1 pph/15M | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,787,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 0.01 pph/6H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,2213,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 5.00 pph/6H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays | TIVIEQ 27,2213,2013 |
| In Vitro/jma | Inhibitor Concentration Low: 0.018 mmol/L/24H | In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Other assays | TIVIEQ 25,1630,2011 |
| In Vitro/jrd | Inhibitor Concentration (50 percent kill): 13.4 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,626,2014 |
| In Vitro/mra | Inhibitor Concentration (25 percent kill): 148 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 216,65,2013 |
| In Vitro/mra | Inhibitor Concentration Low: 1.48 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOLED5 216,65,2013 |
| inhalation/rat | lethal concentration (50 percent kill): 920 mg/m3/4H | Behavioral: General anesthetic Gastrointestinal: Nausea or vomiting Kidney, Ureter, and Bladder: Hematuria | NTIS** OTS0530403 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 50 mg/kg | NTIS** AD277-689 | |
| intraperitoneal/rabbit | lowest published lethal dose: 150 mg/kg | Lung, Thorax, or Respiration: Other changes | JIDIAQ 42,473,1928 |
| intraperitoneal/rat | lethal dose (50 percent kill): 37 mg/kg | JTEHD6 2,657,1977 | |
| intravenous/Dog | lowest published lethal dose: 17 mg/kg | JIDHAN 4,386,1923 | |
| intravenous/rabbit | lowest published lethal dose: 300 mg/kg | Lung, Thorax, or Respiration: Dyspnea Gastrointestinal: Changes in structure or function of salivary glands | AIMDAP 36,724,1925 |
| intravenous/rat | lowest published lethal dose: 50 mg/kg | BSRSA6 41,302,1972 | |
| oral/cat | lowest published lethal dose: 100 mg/kg | Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Respiratory stimulation Nutritional and Gross Metabolic: Body temperature decrease | JIDHAN 4,386,1923 |
| oral/guinea pig | lethal dose (50 percent kill): 145 mg/kg | GISAAA 53(7),62,1988 | |
| oral/man | lowest published toxic dose: 71 mg/kg | Behavioral: Muscle weakness Lung, Thorax, or Respiration: Acute pulmonary edema Lung, Thorax, or Respiration: Dyspnea | HUTODJ 8,345,1989 |
| oral/mouse | lowest published lethal dose: 100 mg/kg | GISAAA 23(5),14,1958 | |
| oral/quail | lethal dose (50 percent kill): 100 mg/kg | AECTCV 12,355,1983 | |
| oral/rabbit | lowest published lethal dose: 250 mg/kg | Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Respiratory stimulation Nutritional and Gross Metabolic: Body temperature decrease | JIDHAN 4,386,1923 |
| oral/rat | lethal dose (50 percent kill): 80 mg/kg | JTEHD6 2,657,1977 | |
| oral/wild bird | lethal dose (50 percent kill): 100 mg/kg | AECTCV 12,355,1983 | |
| skin/rabbit | lowest published lethal dose: 5 gm/kg | JTEHD6 2,657,1977 | |
| subcutaneous/Dog | lowest published lethal dose: 100 mg/kg | Behavioral: Coma Gastrointestinal: Changes in structure or function of salivary glands Gastrointestinal: Nausea or vomiting | XPHBAO 271,40,1941 |
| subcutaneous/mouse | lowest published lethal dose: 140 mg/kg | JSCCA5 12,500,1961 | |
| subcutaneous/rabbit | lowest published lethal dose: 200 mg/kg | Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Respiratory stimulation Nutritional and Gross Metabolic: Body temperature decrease | JIDHAN 4,386,1923 |
| subcutaneous/rat | lowest published lethal dose: 170 mg/kg | Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Dyspnea Lung, Thorax, or Respiration: Respiratory stimulation | JIDHAN 4,386,1923 |
| unreported route/guinea pig | lethal dose (50 percent kill): 145 mg/kg | GTPZAB 31(8),46,1987 | |
| unreported route/mouse | lethal dose (50 percent kill): 331 mg/kg | Brain and Coverings: Other degenerative changes | GISAAA 50(6),78,1985 |
| unreported route/rat | lethal dose (50 percent kill): 133 mg/kg | GTPZAB 31(8),46,1987 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/mouse | lowest published toxic dose: 375 mg/kg/5D- continuous | Behavioral: Food intake (animal) Behavioral: Fluid intake | FCTOD7 43,133,2005 |
| oral/rabbit | lowest published toxic concentration: 105 mg/kg/30W- intermittent | Behavioral: Somnolence (general depressed activity) Liver: Fatty liver degeneration Liver: Liver function tests impaired | GISAAA 23(5),14,1958 |
| oral/rat | lowest published toxic dose: 1050 mg/kg/30W- intermittent | Brain and Coverings: Recordings from specific areas of CNS Behavioral: Alteration of classical conditioning Liver: Fatty liver degeneration | GISAAA 23(5),14,1958 |
| oral/rat | lowest published toxic dose: 28 gm/kg/80W- continuous | Endocrine: Changes in spleen weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOLED5 16,259,1983 |
| oral/rat | lowest published toxic dose: 16800 mg/kg/12W- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOLED5 16,259,1983 |
| skin/rat | lowest published toxic dose: 543.5 mg/kg/9D- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Xanthine oxidases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases | BPBLEO 31,681,2008 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 0.1 mg/m3 | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Not classifiable as a human carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 16,125,1978 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 16,125,1978 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMSUDL 7,56,1987 |
| TOXICOLOGY REVIEW | JACTDZ 4(3),203,1985 | |
| TOXICOLOGY REVIEW | HUTOX* -,419,1996 | |
| TOXICOLOGY REVIEW | MUTAEX 23,271,2008 | |
| TOXICOLOGY REVIEW | TXAPA9 243,239,2010 | |
| TOXICOLOGY REVIEW | TXAPA9 250,87,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 25,17,2010 | |
| TOXICOLOGY REVIEW | MUTAEX 31,453,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 56,54,2010 | |
| TOXICOLOGY REVIEW | RTOPDW 61,1,2011 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 0.1 mg/m3 (skin) | DTLVS* 3,205,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 0.1 mg/m3, JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | TRK-TMW 0.1 mg/m3;KZW 0.4 mg/m3, inhal, skin, sen, 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 0.1 mg/m3, MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 0.1 mg/m3, skin, MAY2011 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 0.1 mg/m3, short term exposure limit 0.3 mg/m3, skin, NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 0.1 mg/m3, Skin, FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 0.1 mg/m3, inhal, skin, sen, 2011 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 0.1 mg/m3, skin, sen, NOV2011 | |
| Occupational Exposure Limit-JAPAN | Occupational Exposure Limit 0.1 mg/m3, s1 sen, MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 0.1 mg/m3, skin, 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 0.1 mg/m3, 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 0.1 mg/m3, skin, JAN2002 | |
| Occupational Exposure Limit-PERU | time-weighted average 0,1 mg/m3, JUL2005 | |
| Occupational Exposure Limit-POLAND | MAC(time-weighted average) 0.1 mg/m3, MAC(short term exposure limit) 0.3 mg/m3, JAN1999 | |
| Occupational Exposure Limit-RUSSIA | short term exposure limit 0.05 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 0.1 mg/m3, KZG-week 0.2 mg/m3, inhal, skin, sen, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 0.1 mg/m3, Skin, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 0.1 mg/m3, Skin, JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 0.1 mg/m3, skin, OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 0.1 mg/m3 (skin) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 0.1 mg/m3 (skin) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 0.1 mg/m3 (skin) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 0.1 mg/m3 (skin) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO p-PHENYLENE DIAMINE-air | 10H time-weighted average 0.1 mg/m3 (Sk) | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 56950; Number of Industries 6; Total Number of Facilities 5390; Number of Occupations 7; Total Number of Employees Exposed 49939; Total Number of Female Employees Exposed 37209 | |
| National Occupational Hazard Survey 1974 | Hazard Code 56950; Number of Industries 9; Total Number of Facilities 2017; Number of Occupations 11; Total Number of Employees Exposed 14983 |
Status in Federal Agencies
| Organization | Reference |
|---|---|
| EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus | |
| EPA GENETOX PROGRAM 1988, Negative: Carcinogenicity-mouse/rat; Rodent dominant lethal | |
| EPA GENETOX PROGRAM 1988, Negative: N crassa-aneuploidy; Sperm morphology-mouse | |
| EPA GENETOX PROGRAM 1988, Positive: Cell transform.-RLV F344 rat embryo | |
| EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; D melanogaster Sex-linked lethal | |
| EPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE | FEREAC 47,26992,82 |
| EPA TSCA Section 8(b) CHEMICAL INVENTORY | |
| EPA TSCA Section 8(d) unpublished health/safety studies | |
| EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 | |
| OSHA ANALYTICAL METHOD #87 |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health